BioCentury
ARTICLE | Clinical News

Krystexxa pegloticase regulatory update

July 1, 2013 7:00 AM UTC

The U.K.'s NICE issued final guidance recommending against the use of Krystexxa pegloticase from Savient to treat severe chronic tophaceous gout in adult patients - its approved indication. The guidan...